SCHEMBL4868085

SCHEMBL4868085

O=C(O)c1cc2c(s1)c(C1CCCCC1)c(-c1ccc3nc(-c4ccc(Cl)s4)ccc3c1)n2Cc1ccncc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 8/20 0.33
F2 P00734 3/20 0.33
KDM4E B2RXH2 1/20 0.32
MEN1 O00255 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
GLA P06280 1/20 0.32
GAA P10253 1/20 0.32
PPARG P37231 1/20 0.32
KMT2A Q03164 1/20 0.32
NCOA2 Q15596 1/20 0.32
NCOA1 Q15788 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
DHODH Q02127 1/20 0.32
MCHR1 Q99705 1/20 0.32
PLAT P00750 1/20 0.31
KLK1 P06870 1/20 0.31
FBP1 P09467 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4879012 0.89 ALOX5AP (0.35) MCHR1ALOX5AP
SCHEMBL4866901 0.88 GRIN1 (0.33) ALOX5AP
SCHEMBL4875175 0.87 ERCC5 (0.38) KDM4EPPARGSMN1; SMN2ALOX5AP
SCHEMBL4877200 0.87 KDM4E (0.33) KDM4EALDH1A1LMNASMN1; SMN2DHODH
SCHEMBL4872478 0.86 KCNH2 (0.39) MEN1KMT2A
SCHEMBL4873267 0.86 ALOX5AP (0.34) ALDH1A1GAAALOX5AP
SCHEMBL4867590 0.85 ALOX5AP (0.35) PPARGDHODHALOX5AP
SCHEMBL4868096 0.85 KDM4E (0.39) F10F2KDM4EMEN1ALDH1A1
SCHEMBL4878276 0.85 MAOA (0.36) LMNAPPARGRXFP1DHODHALOX5AP
SCHEMBL4872012 0.84 MDM2 (0.35) DHODHALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 F10 3206/4885F2 2088/4885KDM4E 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.